Rocket Pharmaceuticals (RCKT) Capital Expenditures (2015 - 2025)

Rocket Pharmaceuticals has disclosed Capital Expenditures across 11 years of filings, most recently posting $440000.0 for Q4 2025.

• Capital Expenditures for Q4 2025 came in at $440000.0, up 42.39% year-over-year; the trailing twelve-month figure through Mar 2026 was $389000.0 (down 89.97% YoY), and the FY2025 annual result was $440000.0, down 92.49% from the prior year.
• Capital Expenditures came in at $440000.0 for Q4 2025 at Rocket Pharmaceuticals, up from -$414000.0 in the prior quarter.
• In the past five years, Capital Expenditures ranged from a high of $10.5 million in Q3 2023 to a low of -$3.3 million in Q4 2022.
• The 5-year median for Capital Expenditures is $1.5 million (2021), against an average of $1.6 million.
• Across the five-year window, Capital Expenditures plunged 265.9% in 2022 and jumped 1992.25% in 2023, its largest moves.
• Rocket Pharmaceuticals' Capital Expenditures stood at $2.0 million in 2021, then slumped by 265.9% to -$3.3 million in 2022, then surged by 242.55% to $4.6 million in 2023, then tumbled by 93.35% to $309000.0 in 2024, then jumped by 42.39% to $440000.0 in 2025.
• The last three Capital Expenditures figures came in at $440000.0 (Q4 2025), -$414000.0 (Q3 2025), and $363000.0 (Q2 2025), per Business Quant data.